Standard of Excellence: ‘Quality’ Is Your Company's Greatest Competitive Advantage
Powering the Future: From Substrate to System—The Power Module Assembly
Global Sourcing Spotlight: Global Sourcing in the Age of Constant Uncertainty 
Schweitzer Engineering Laboratories (SEL), a global leader in power system protection, automation and control solutions, announced today its expansion into medical devices with the production of a tool for detecting the likelihood of autism spectrum disorder.
Dr. Georgina Lynch recently joined SEL as principal scientist after inventing and leading the development of a prototype while at Washington State University (WSU). Dr. Lynch holds a PhD in neuroscience/psychology and has a background in speech-language pathology and more than 20 years of experience working with children with autism.
“We are excited about Dr. Lynch’s invention, and delighted that we can further its development, pursue approvals and begin production,” said Edmund O. Schweitzer, III, SEL founder and chairman of the board of the Pullman, Washington-based laboratories. “It makes screening for autism as simple as taking pictures. So many families, including mine, are impacted by autism. Georgina’s invention will accelerate earlier diagnosis and treatment.”
SEL has created a medical devices team to pursue this new technology.
“When Dr. Schweitzer first introduced the idea of manufacturing the device to our leadership team, he said, ‘Bringing this invention to the market where it will help so many children and families is important work. We are experts in digital signal processing, sensor technology, manufacturing, compliance, sales, and marketing. So, we should do it!’” recalled Travis Mooney, vice president of Research & Development.
The device, which can detect an atypical pupil light reflex and the likelihood of autism within 24 months of birth, is a handheld tool to be used by clinicians during well-child exams. Earlier indications lead to care at younger ages.
“We know that earlier intervention positively impacts outcomes for children with autism,” said Lynch. “It can mean the difference between a child acquiring verbal speech or remaining nonverbal. With the average diagnosis age at 49 months, this technology could lower that age due to its objectivity, giving children up to two extra years of crucial intervention.”
This innovation aims to expedite the diagnostic process for families, reduce the associated stress, and ultimately improve outcomes for children with autism.
“From the beginning, our hope was to commercialize this technology and make it widely available, and after getting to know Dr. Schweitzer and learning about SEL, I felt it was the best company to do this,” said Lynch.
Dr. Lynch and her team are working through the FDA regulatory and compliance requirements.
“It just feels right, that SEL, itself born from research at Washington State University, now has the honor of bringing this new WSU technology to life,” added Dr. Schweitzer. “Invented by Cougs, developed by Cougs, …and soon to be manufactured, sold, and supported by Cougs.”
